(Q72394484)
Statements
A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma (English)
P Lissoni
S Barni
A Ardizzoia
M Andres
E Scardino
P Cardellini
R Della Bitta
1 December 1993